Milnacipran의 섬유근통 증후군치료에 대한 연구 검토

키워드

참고문헌 (24)

2. Wolfe F, "The prevalence and characteristics of fibromyalgia in the general population", Arthritis Rheum, 38, pp.19~28 (1995)
3. 김성호, "한국의 두 지역사회에서 섬유근통 증후군과만성 광범위 통증의 유병률과 위험요인", 대한류마티스학회지, 13(1), pp.18~25 (2006), 대한류마티스학회
4. Wolfe F, "Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms", J Rheumatol, 22, pp.151~156 (1995)
5. Navarro RP, "Contemporary management strategies for fibromyalgia", Am J Manag Care, 15, pp.S197~218 (2009)
6. WolfeF, "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee", Arthritis Rheum, 33, pp.160~172 (1990)
7. Bennett R, "Fibromyalgia: present to future", CurrRheumatol Rep, 7, pp.371~376 (2005)
8. Abeles AM, "Narrative review:the pathophysiology of fibromyalgia", Ann Intern Med, 146, pp.726~734 (2007)
9. Goldenberg DL, "Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain", Best Pract Res ClinRheumatol, 21, pp.499~511 (2007)
10. Abeles M, "Update on fibromyalgia therapy", Am J Med, 121, pp.555~561 (2008)
11. Savella, "Clinical Pharmacology, database online", FL: Gold Standard, Inc; expires 2010 Dec 31 (accessed July 26, 2010), ~ (2010)
13. Jones CK, "Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition", Neuropharmacology, 51, pp.1172~1180 (2006)
14. Obata H, "The monoaminemediated antiallodynic effects ofintrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain", AnesthAnalg, 100, pp.1406~1410 (2005)
15. Product information, "Savella (milnacipran)" (2009), Forest Pharmaceuticals, Inc
16. Puozzo C, "Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants", ClinPharmacokinet, 44, pp.977~988 (2005)
17. Puozzo C, "Pharmacology and pharmacokinetics of milnacipran", IntClinPsychopharmacol, 17(Suppl 1), pp.S25~S35 (2002)
18. Vaishnavi SN, "Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity", Biol Psychiatry, 55, pp.320~322 (2004)
19. Gendreau RM, "Efficacy of milnacipran in patients with fibromyalgia", J Rheumatol, 32, pp.1975~1985 (2005)
20. Clauw DJ, "Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clnical trial", ClinTher, 30, pp.1988~2004 (2008)
21. Mease PJ, "The efficacy and safety of milnacipran for the treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial", J Rheumatol, 36, pp.398~409 (2009)
22. Goldenberg DL, "Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study", Pain Med, 11, pp.180~194 (2010)
23. Arnold LM, "Efficacy and safety of milnacipran 100 mg", day in patients with fibromyalgia: results of a randomized, double-blind, placebocontrolled trial, 2010, pp.62, 2745~2756
24. Branco JC, "A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia", J Rheumaol, 37, pp.851~859 (2010)

관련 논문AI추천